A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results

@article{Coronel2011ADP,
  title={A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results},
  author={J. Coronel and L. Cetina and I. Pacheco and C. Trejo-Becerril and A. Gonz{\'a}lez-Fierro and E. De la Cruz-Hernandez and E. P{\'e}rez-C{\'a}rdenas and L. Taja-Chayeb and Daymi Arias-Bofill and M. Candelaria and S. Vidal and A. Duenas-Gonzalez},
  journal={Medical Oncology},
  year={2011},
  volume={28},
  pages={540-546}
}
  • J. Coronel, L. Cetina, +9 authors A. Duenas-Gonzalez
  • Published 2011
  • Medicine
  • Medical Oncology
  • The reversing of epigenetic aberrations using the inhibitors of DNA methylation and histone deacetylases may have therapeutic value in cervical cancer. This is a randomized phase III, placebo-controlled study of hydralazine and valproate (HV) added to cisplatin topotecan in advanced cervical cancer. Patients received hydralazine at 182 mg for rapid, or 83 mg for slow acetylators, and valproate at 30 mg/kg, beginning a week before chemotherapy and continued until disease progression. Response… CONTINUE READING
    104 Citations
    Emerging drugs for the treatment of cervical cancer
    • 16
    New molecular targets against cervical cancer
    • 36
    • PDF

    References

    SHOWING 1-10 OF 45 REFERENCES
    Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers
    • 150
    • PDF
    Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.
    • K. Appleton, H. Mackay, +15 authors R. Brown
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2007
    • 206
    A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors
    • 69
    • PDF
    Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes
    • 94
    • PDF